Drug Trial Radar · NCT07942766
A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIa, open-label, multicenter clinical trial that plans to enroll approximately 20 patients each with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to prior therapies. Participants will receive 12 weeks of the investigational study drug to provide a preliminary assessment of its efficacy and safety.
Conditions
- Inflammatory Bowel Disease (IBD)
Interventions
HW201877 capsulesDrug
HW201877 oral capsule,12W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 • Proportion of participants achieving clinical remission based on the modified Mayo score at Week 12;Time frame: At week 12
- Cohort 2 Co-primary endpoints: • Proportion of participants achieving symptomatic remission at Week 12;Time frame: At week 12
- Cohort 2 Co-primary endpoints: • Proportion of participants achieving endoscopic response at Week 12.Time frame: At week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renmin hospital of Wuhan University
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.